These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 29923083)

  • 21. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis.
    Zhang J; Zhang L; Wang J; Zhao J; Zhao X; Zhang C; Han P; Geng C
    Hum Cell; 2022 May; 35(3):909-923. PubMed ID: 35179718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
    Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
    Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
    Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.
    Ding L; Gu H; Xiong X; Ao H; Cao J; Lin W; Yu M; Lin J; Cui Q
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer.
    Hu J; Xu J; Wu Y; Chen Q; Zheng W; Lu X; Zhou C; Jiao D
    Tumour Biol; 2015 Jan; 36(1):251-8. PubMed ID: 25238878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression.
    Yang R; Xing L; Zheng X; Sun Y; Wang X; Chen J
    Mol Cancer; 2019 Jan; 18(1):4. PubMed ID: 30621700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
    Han C; Fu Y; Zeng N; Yin J; Li Q
    Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
    Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
    Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
    Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
    Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
    Bai X; Han G; Liu Y; Jiang H; He Q
    Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.
    Han C; Li X; Fan Q; Liu G; Yin J
    Aging (Albany NY); 2019 Jul; 11(14):4858-4875. PubMed ID: 31310241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.
    Toda H; Kurozumi S; Kijima Y; Idichi T; Shinden Y; Yamada Y; Arai T; Maemura K; Fujii T; Horiguchi J; Natsugoe S; Seki N
    J Hum Genet; 2018 Dec; 63(12):1197-1210. PubMed ID: 30228364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
    Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.
    Shin VY; Siu JM; Cheuk I; Ng EK; Kwong A
    Br J Cancer; 2015 May; 112(11):1751-9. PubMed ID: 25906045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.